NEW YORK (TheStreet) -- Medicines Co.(MDCO) - Get Report shares are up 7.62% to $30.50 in afternoon trading Thursday but may be in danger of falling after the company announced that a federal circuit court ruled against the company's patent infringement claims against Hospira (HSP) .
The pharmaceutical company announced that the U.S. District Court of Delaware ruled that the company's claims that its '727 and '343 patents covering Angiomax were valid but that those patents were not infringed by Hospira's ANDA products.
Both companies appealed the ruling with Medicines Co. appealing the claim construction and non-infringement rulings. Hospira appealed the patent validity findings.
"We are evaluating today's court ruling and considering our next steps. We remain committed to interventional cardiovascular medicine and will continue to support bivalirudin," said Medicines CEO Clive Meanwell.
TheStreet Ratings team rates MEDICINES CO as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation:
"We rate MEDICINES CO (MDCO) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: MDCO Ratings Report